RetaspimycinHSP90 inhibitor,antiproliferative and antineoplastic CAS# 857402-23-4 |
- Radicicol
Catalog No.:BCC2131
CAS No.:12772-57-5
- NVP-BEP800
Catalog No.:BCC2129
CAS No.:847559-80-2
- BIIB021
Catalog No.:BCC2124
CAS No.:848695-25-0
- IPI-504 (Retaspimycin hydrochloride)
Catalog No.:BCC2126
CAS No.:857402-63-2
- 17-AAG Hydrochloride
Catalog No.:BCC1297
CAS No.:911710-03-7
- MPC-3100
Catalog No.:BCC2128
CAS No.:958025-66-6
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 857402-23-4 | SDF | Download SDF |
PubChem ID | 11534420 | Appearance | Powder |
Formula | C31H45N3O8 | M.Wt | 587.7 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Synonyms | IPI-504 | ||
Solubility | Soluble in DMSO | ||
Chemical Name | [(4E,6Z,8S,9S,10E,12S,13R,14S,16R)-13,20,22-trihydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-3-oxo-19-(prop-2-enylamino)-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18(22),19-hexaen-9-yl] carbamate | ||
SMILES | CC1CC(C(C(C=C(C(C(C=CC=C(C(=O)NC2=CC(=C(C(=C2O)C1)NCC=C)O)C)OC)OC(=O)N)C)C)O)OC | ||
Standard InChIKey | OAKGNIRUXAZDQF-TXHRRWQRSA-N | ||
Standard InChI | InChI=1S/C31H45N3O8/c1-8-12-33-26-21-13-17(2)14-25(41-7)27(36)19(4)15-20(5)29(42-31(32)39)24(40-6)11-9-10-18(3)30(38)34-22(28(21)37)16-23(26)35/h8-11,15-17,19,24-25,27,29,33,35-37H,1,12-14H2,2-7H3,(H2,32,39)(H,34,38)/b11-9-,18-10+,20-15+/t17-,19+,24+,25+,27-,29+/m1/s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Retaspimycin is a small-molecule inhibitor of heat shock protein 90 (HSP90). | |||||
Targets | HSP90 |
Retaspimycin Dilution Calculator
Retaspimycin Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 1.7015 mL | 8.5077 mL | 17.0155 mL | 34.031 mL | 42.5387 mL |
5 mM | 0.3403 mL | 1.7015 mL | 3.4031 mL | 6.8062 mL | 8.5077 mL |
10 mM | 0.1702 mL | 0.8508 mL | 1.7015 mL | 3.4031 mL | 4.2539 mL |
50 mM | 0.034 mL | 0.1702 mL | 0.3403 mL | 0.6806 mL | 0.8508 mL |
100 mM | 0.017 mL | 0.0851 mL | 0.1702 mL | 0.3403 mL | 0.4254 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Retaspimycin is a water-soluble hydroquinone hydrochloride salt inhibitor of Hsp90 [1].
Hsp90 is a member of the Hsp family. The other members of this protein family are Hsp40, Hsp70 and so on. These proteins act as molecule chaperons and participate in many cellular processes. When cells are exposed in stress, some proteins become unstable, accumulate to form aggregates and subsequently cause cell apoptosis. In this situation, Hsps will help their client proteins folding correctly, accompany them to be translocated to the correct location and thus prevent the cells from apoptosis. Hsps are required for cancer cells development. They are found to overexpress in a variety of cancer cells. Therefore, the inhibitors of Hsp are thought to be attractive therapy for cancer treatment. As an inhibitor of Hsp90, retaspimycin works through binding to the ATP-binding pocket of Hsp90 N-terminal [1].
In both RPMI-8826 and MM1.S cells, treatment of retaspimycin resulted in degradation of the Hsp90 client proteins, for instance, c-RAF and Her2. It also caused increased levels of Hsp70. Besides that, retaspimycin is found to prevent RPMI-8826 cells from secreting the immunoglobulin light chain. In breast cancer cells which are resistant to trastuzumab, treatment of retaspimycin potently caused Her2 degradation and resulted in tumor growth suppression and cell apoptosis [1].
Retaspimycin is often used as combination therapy with other drugs in cancer treatment. In mice bearing GIST-882 (gastrointestinal stromal tumor) xenografts, the administration of retaspimycin associated with imatinib showed a significant effect with a 66% tumor regression. In mice bearing GIST-PSW xenografts, both the combination treatment of retaspimycin and imatinib or sunitinib showed effective antitumor activities in reducing tumor burden. When used alone, retaspimycin reduced tumor volumes by 84% and 69% in GIST-PSW and GIST-882 mice models, respectively. Moreover, retaspimycin is found to decrease the mitotic activity in these two models. However, the antimitotic effects of retaspimycin were less significant than of imatinib or sunitinib or the combination treatment [2].
References:
[1]. Hanson B E, Vesole D H. Retaspimycin hydrochloride (IPI-504): a novel heat shock protein inhibitor as an anticancer agent. 2009.
[2]. Floris G, Debiec-Rychter M, Wozniak A, et al. The heat shock protein 90 inhibitor IPI-504 induces KIT degradation, tumor shrinkage, and cell proliferation arrest in xenograft models of gastrointestinal stromal tumors. Molecular cancer therapeutics, 2011, 10(10): 1897-1908.
- Isoflavidinin
Catalog No.:BCN7604
CAS No.:85734-02-7
- 3-Hydroxysarpagine
Catalog No.:BCN4566
CAS No.:857297-90-6
- PF 915275
Catalog No.:BCC7631
CAS No.:857290-04-1
- TMC353121
Catalog No.:BCC2004
CAS No.:857066-90-1
- WP1066
Catalog No.:BCC2194
CAS No.:857064-38-1
- Scopine HCl
Catalog No.:BCC4940
CAS No.:85700-55-6
- (3S,3'R,8R,9R,9As)-8-methoxy-3'-methyl-3-[(2S,4S)-4-methyl-5-oxooxolan-2-yl]spiro[1,2,3,5,6,7,8,9a-octahydropyrrolo[1,2-a]azepine-9,5'-oxolane]-2'-one
Catalog No.:BCC9250
CAS No.:85700-47-6
- alpha-Conidendrin
Catalog No.:BCN4407
CAS No.:85699-62-3
- (-)-Blebbistatin
Catalog No.:BCC4375
CAS No.:856925-71-8
- Tedizolid
Catalog No.:BCC1990
CAS No.:856866-72-3
- AM 114
Catalog No.:BCC3589
CAS No.:856849-35-9
- CBiPES hydrochloride
Catalog No.:BCC7824
CAS No.:856702-40-4
- IPI-504 (Retaspimycin hydrochloride)
Catalog No.:BCC2126
CAS No.:857402-63-2
- K-252c
Catalog No.:BCC3706
CAS No.:85753-43-1
- AT7867
Catalog No.:BCC2536
CAS No.:857531-00-1
- PSN632408
Catalog No.:BCC5408
CAS No.:857652-30-3
- Longistylumphylline A
Catalog No.:BCN4408
CAS No.:857672-34-5
- Alstolenine
Catalog No.:BCN4808
CAS No.:85769-33-1
- Polygalaxanthone XI
Catalog No.:BCN7366
CAS No.:857859-82-6
- Motesanib Diphosphate (AMG-706)
Catalog No.:BCC2477
CAS No.:857876-30-3
- 11,12-Di-O-acetyltenacigenin B
Catalog No.:BCN4565
CAS No.:857897-01-9
- (-)-Quinpirole hydrochloride
Catalog No.:BCC6917
CAS No.:85798-08-9
- 3-O-Benzyl estrone
Catalog No.:BCC8638
CAS No.:858-98-0
- Vialinin A
Catalog No.:BCC2367
CAS No.:858134-23-3
Multicenter phase II trial of the heat shock protein 90 inhibitor, retaspimycin hydrochloride (IPI-504), in patients with castration-resistant prostate cancer.[Pubmed:21762967]
Urology. 2011 Sep;78(3):626-30.
OBJECTIVE: To evaluate clinical activity and safety of Retaspimycin hydrochloride (IPI-504) in patients with castration-resistant prostate cancer (CRPC). METHODS: A single-arm trial was conducted in 2 cohorts: group 1, chemotherapy naive; group 2, docetaxel-treated. IPI-504 was administered intravenously at 400 mg/m2 on days 1, 4, 8, and 11 of a 21-day cycle. Trial expansion was planned if >/=1 prostate-specific antigen (PSA) or radiographic response was noted per cohort. Pharmacokinetic samples were collected after the first dose; safety was assessed throughout. RESULTS: A total of 19 patients were enrolled (4 in group 1; 15 in group 2), with a median age of 66 years (range 49-78). Group 2 had received a median of 2 previous chemotherapy regimens. All group 2 patients had bone metastases; 66% had measurable soft tissue or visceral metastases. One group 1 patient remained on-trial for 9 cycles; his PSA level declined 48% from baseline. No PSA response was observed in the other patients. Adverse events reported in >25% of the study population included nausea (47%), diarrhea (42%), fatigue (32%), anorexia (26%), and arthralgia (26%). Two patients in group 2 died on-trial, involving study drug-related events of hepatic failure and ketoacidosis, respectively. CONCLUSION: Heat shock protein 90 inhibition with IPI-504 administered as a single agent had a minimal effect on the PSA level or tumor burden and was associated with unacceptable toxicity in several patients. Therefore, additional evaluation in CRPC patients is not warranted. IPI-504 is being investigated at less-intensive doses and schedules in other tumor types.
A phase 1 study of IPI-504 (retaspimycin hydrochloride) in patients with relapsed or relapsed and refractory multiple myeloma.[Pubmed:21851215]
Leuk Lymphoma. 2011 Dec;52(12):2308-15.
Abstract A phase 1 study of IPI-504 (Retaspimycin hydrochloride) administered intravenously twice weekly for 2 weeks at 22.5, 45, 90, 150, 225, 300 or 400 mg/m(2) followed by 10 days off-treatment was conducted to determine the safety and maximum tolerated dose (MTD) of IPI-504 in patients with relapsed or relapsed/refractory multiple myeloma (MM). Anti-tumor activity and pharmacokinetics were also evaluated. Eighteen patients (mean age 60.5 years; median 9 prior therapies) were enrolled. No dose-limiting toxicities (DLTs) were reported for IPI-504 doses up to 400 mg/m(2). The most common treatment-related adverse event was grade 1 infusion site pain (four patients). All other treatment-related events were assessed as grade 1 or 2 in severity. The area under the curve (AUC) increased with increasing dose, and the mean half-life was approximately 2-4 h for IPI-504 and its metabolites. Four patients had stable disease, demonstrating modest single-agent activity in relapsed or relapsed/refractory MM.
A multicenter trial evaluating retaspimycin HCL (IPI-504) plus trastuzumab in patients with advanced or metastatic HER2-positive breast cancer.[Pubmed:23580070]
Breast Cancer Res Treat. 2013 May;139(1):107-13.
Heat shock protein 90 (Hsp90) facilitates maturation and stability of HER2. Combining an Hsp90 inhibitor and trastuzumab has demonstrated anti-tumor effects in patients with HER2+ breast cancer. Adults with measurable, locally advanced or metastatic HER2+ breast cancer and prior trastuzumab treatment were enrolled in a phase 2 trial employing weekly 300 mg/m(2) Retaspimycin HCl, a potent Hsp90 inhibitor, with 6 mg/kg trastuzumab every 3 weeks. A Simon's two-stage design determined trial expansion by dose-limiting toxicity (DLT) and response rates. Pharmacokinetics and electrocardiograms were evaluated. Twenty-six patients with median age 52.5 years (range 33-72) enrolled with a median of six prior chemotherapeutic regimens (range 2-20). On study, patients received a median of three treatment cycles (range 1-12). No DLTs were observed. Most adverse events (AEs) were grade 1 or 2; common treatment-related AEs included fatigue (46 %), nausea (31 %), and diarrhea (23 %). One patient had treatment-related serious AEs of grade 1 diarrhea and grade 3 hypokalemia. grade 3 transaminase elevation occurred in one patient (4 %) who also had metastatic liver disease. Sixteen patients (62 %) had stable disease, with a median on-study duration of 2.4 months (range 1.1-8.2). No confirmed responses were observed. Retaspimycin HCl at 300 mg/m(2) weekly in combination with trastuzumab was well tolerated and without significant toxicities. Modest clinical activity was observed, but did not meet criteria for trial expansion. The safety profile for patients on study raises the possibility of Retaspimycin HCl underdosing that limited efficacy. Studies employing higher doses are ongoing.
A phase I study of the HSP90 inhibitor retaspimycin hydrochloride (IPI-504) in patients with gastrointestinal stromal tumors or soft-tissue sarcomas.[Pubmed:24045182]
Clin Cancer Res. 2013 Nov 1;19(21):6020-9.
PURPOSE: Heat shock protein 90 (HSP90) is required for the proper folding, function, and stability of various client proteins, two of which (KIT and PDGFRalpha) are critical in the pathogenesis and progression of gastrointestinal stromal tumors (GIST). This phase I study investigated the safety and maximum tolerated dose (MTD) of Retaspimycin hydrochloride (IPI-504), a novel potent and selective HSP90 inhibitor, in patients with metastatic and/or unresectable GIST or other soft-tissue sarcomas (STS). EXPERIMENTAL DESIGN: IPI-504 was administered intravenously at doses ranging from 90 to 500 mg/m(2) twice weekly for 2 weeks on/1 week off. Safety, pharmacokinetic, and pharmacodynamic profiles were determined. Response was assessed by Response Evaluation Criteria for Solid Tumors (RECIST) 1.0 and optionally via 18-fluorodeoxyglucose positron emission tomography (18-FDG-PET) imaging. RESULTS: Fifty-four patients received IPI-504; 37 with GIST and 17 with other STS. The MTD was 400 mg/m(2) twice weekly for 2 weeks on/1 week off. Common related adverse events were fatigue (59%), headache (44%), and nausea (43%). Exposure to IPI-504, 17-AAG, and 17-AG increased with IPI-504 dose. Stable disease (SD) was observed in 70% (26 of 37) of patients with GIST and 59% (10 of 17) of patients with STS. There was one confirmed partial response (PR) in a patient with GIST and one PR in a patient with liposarcoma. Metabolic partial responses occurred in 11 of 29 (38%) patients with GIST. CONCLUSIONS: In this study of advanced GIST or other STS, IPI-504 was generally well-tolerated with some evidence of antitumor activity, serving as a clinical proof-of-concept that HSP90 inhibition remains a promising strategy.